Market capitalization | $296.09m |
Enterprise Value | $55.68m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.83 |
P/S ratio (TTM) P/S ratio | 4.42 |
P/B ratio (TTM) P/B ratio | 1.28 |
Revenue growth (TTM) Revenue growth | 247.03% |
Revenue (TTM) Revenue | $67.03m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
18 Analysts have issued a Editas Medicine, Inc. forecast:
18 Analysts have issued a Editas Medicine, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 67 67 |
247%
247%
|
|
Gross Profit | 61 61 |
369%
369%
|
|
EBITDA | -207 -207 |
1%
1%
|
EBIT (Operating Income) EBIT | -213 -213 |
1%
1%
|
Net Profit | -193 -193 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Gilmore O’Neill |
Employees | 265 |
Founded | 2013 |
Website | www.editasmedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.